NCT03735290View on ClinicalTrials.gov

A Study to Evaluate the Safety and Effectiveness of ILIxadencel Administered Into Tumors in Combination With Checkpoint Inhibitor (CPI) in Patients With ADvanced Cancer

PHASE1TerminatedINTERVENTIONAL
Enrollment

21

Participants

Timeline

Start Date

January 14, 2019

Primary Completion Date

December 3, 2021

Study Completion Date

December 3, 2021

Conditions
Carcinoma, Squamous Cell of Head and NeckGastric AdenocarcinomaGastroesophageal Junction AdenocarcinomaNon-small Cell Lung Cancer
Interventions
BIOLOGICAL

ilixadencel

Intra-tumoral injection

DRUG

Pembrolizumab

Administered intravenously over 30 minutes, every 3 weeks, at a dose of 200 mg

Trial Locations (5)

27514

Site 1004, Chapel Hill

33124

Site 1010, Coral Gables

40202

Site 1011, Louisville

44106

Site 1009, Cleveland

52242

Site 1006, Iowa City

Sponsors

Lead Sponsor

Mendus

Collaborators (1)

PPD Development, LP
All Listed Sponsors
collaborator

PPD Development, LP

INDUSTRY

lead

Mendus

INDUSTRY

NCT03735290 - A Study to Evaluate the Safety and Effectiveness of ILIxadencel Administered Into Tumors in Combination With Checkpoint Inhibitor (CPI) in Patients With ADvanced Cancer | Biotech Hunter | Biotech Hunter